Morphological characteristics of uterine fibroids among women of reproductive age

Cover Page

Abstract


The article deals with modern views on etiopathogenesis of uterine fibroids. Increased knowledge of the markers of proliferation and their study will help to predict the course of the disease and thus to develop the optimum tactics of the further treatment of the early stages. Much attention is paid to the study of markers that characterize apoptosis. By immunohistochemistry in tissue fibroids 15 patients studied protein expression Ki-67 and Bcl-2. Analyzed values of the correlation expression of the proteins according to the clinical and morphological features of the tumor. It showed a reduction in the proliferation marker Ki-67, and increased expression of apoptotic Bcl-2 inhibitor.

Background. Presented by changes in the nature of proliferation and apoptotic activity in myoma nodes among women of reproductive age who underwent conservative myomectomy.

The aim of the research was to study the performance of protein antibody Ki-67 proliferation and apoptosis inhibitor of Bcl-2 in women with uterine myoma.

Material and methods. Surveyed 15 women with uterine fibroids who underwent conservative myomectomy. Inclusion criteria were: the reproductive age, uterine fibroids the size of which does not exceed the 12-week pregnancy. Exclusion criteria were the size of fibroids greater than 12 weeks of pregnancy, acute inflammatory diseases of the pelvic organs, severe somatic diseases, cancer of the reproductive organs. It was carried out histological and immunohistochemical study of remote myoma node. We examined by immunohistochemistry proliferation protein monoclonal antibody Ki-67 (Clone MIB-1, 1 : 150, Dako), inhibitor of apoptosis Bcl-2 (NCL-bcl-2-486). (Novocastra). Evaluation of the expression of markers studied conducted qualitative and quantitative methods in computer image analysis system “Morphology 5.0” (Video Test, Russia). Statistical processing of the results was performed using statistical analysis packages (STATGRAPHICS v. 6.0).

Results. Age of women surveyed averaged 33,4 ± 4,1 years. Histological study of benign tumors of the uterus body showed the presence of degenerative changes, necrosis and inflammatory infiltration in every fourth case of the material.

Conclusions. Immunogistohimichesoe study of uterine leiomyomas body revealed a significant increase in the expression of apoptosis inhibitor of Bcl-2 and reducing the proliferation marker Ki-receptor expression in all 67 tested samples, which is consistent with a histological study of the absence of mitotic activity in leiomyomas.


Saodat M Safarova

Author for correspondence.
mahmadulloevas@gmail.com
Tajik Research Institute of Obstetrics, Gynecology and Perinatology
Russian Federation

graduate student

  • Тихомиров А.Л. Миома, патогенетическое обоснование органосохраняющего лечения. – М., 2013. [Tihomirov AL. Mioma, patogeneticheskoe obosnovanie organosohranjajushhego lechenija. Moscow, 2013. (In Russ.)]
  • Khan AT, Shehmar M, Gupta JK. Uterine fibroids: current perspectives. Int J Womens Health. 2014;6:95-114. doi: 10.2147/IJWH.S51083.
  • Engman M, Granberg S, Williams AR, et al. Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Hum Reprod. 2009;24(8):1870-9. doi: 10.1093/humrep/dep100.
  • Радзинский В.Е., Архипова М.П. Миома матки: проблемы и перспективы начала века // Медицинский совет. – 2014. – № 9. – С. 30–33. [Radzinskij VE, Arhipova MP. Mioma matki: problemy i perspektivy nachala vek. Medicinskij sovet. 2014;(9):30-33. (In Russ.)]
  • Сидорова И.С., Коган Е.А, Зайратьянц О.В., и др. Роль процессов апоптоза и пролиферации в патогенезе простой и пролиферирующей миомы матки в сочетании с аденомиозом // Врач. – 2006. – № 14. – С. 8–12. [Sidorova IS, Kogan EA, Zajrat’janc OV, et al. Rol’ processov apoptoza i proliferacii v patogeneze prostoj i proliferirujushhej miomy matki v sochetanii s adenomiozom. Vrach. 2006;(14):8-12. (In Russ.)]
  • Вихляева В.М. Руководство по диагностике и лечению лейомиомы матки. – М.: Медпресс-информ, 2004. [Vihljaeva VM. Rukovodstvo po diagnostike i lecheniju leiomiomy matki. Moscow: Medpress-inform; 2004. (In Russ.)]
  • Сидорова И.С. Миома матки: современные аспекты этиологии, патогенеза, классификации и профилактики. – М.: МИА, 2003. [Sidorova IS. Mioma matki: sovremennye aspekty jetiologii, patogeneza, klassifikacii i profilaktiki. Moscow: MIA; 2003. (In Russ.)]
  • Толибова Г.Х. Сравнительная оценка морфологических критериев эндометриальной дисфункции у пациенток с первичным бесплодием, ассоциированным с воспалительными заболеваниями малого таза, наружным генитальным эндометриозом и миомой матки // Журнал акушерства и женских болезней. – 2016. – № 6. – С. 45–51. [Tolibovа GKh. Comparative evaluation of morphological criteria of endometrial dysfunction in patients with infertility associated with pelvic inflammatory disease, external genital endometriosis and uterine myoma. Journal of Obstetrics and Women’s Diseases. 2016;(6):45-51. (In Russ.)]
  • Чепик О.Ф. Морфогенез гиперпластических процессов эндометрия // Практ. онкол. – 2004. – № 1. – С. 9–15. [Chepik OF. Morfogenez giperplasticheskih processov jendometrija. Prakt. onkol. 2004;(1):9-15. (In Russ.)]
  • Khan KN, Kitajima M, Hiraki K, et al. Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy. Hum Reprod. 2010;25(3):642-53. doi: 10.1093/humrep/dep437.
  • Kim MD, Kim S, Kim NK, et al. Long term results of UAE for symptomatic adenomyosis. Am J Roentgenol. 2007;188(1):176-81. doi: 10.2214/AJR.05.1613.
  • Lohle PN, De Vries J, Klazen CA, et al. Uterine artery embolization for symptomatic adenomyosis with or without uterine leiomyomas with the use of calibrated tris-acryl gelatin microspheres: midterm clinical and MR imaging follow-up. J Vasc Interv Radiol. 2007;18(7):835-41. doi: 10.1016/j.jvir.2007.04.024.
  • Бохман Я.В., Рыбин Е.П. Полинеоплазии органов репродуктивной системы. – СПб.: Нева, 2001. [Bohman JaV, Rybin EP. Polineoplazii organov reproduktivnoi sistemy. Saint Petersburg: Neva; 2001. (In Russ.)]
  • Литвинова Н.А. Состояние эндометрия у больных с сочетанной патологией эндо- и миометрия, перенесших эмболизацию маточных артерий в пременопаузальном возрасте: автореф. дис. … канд. мед. наук. – СПб., 2009. [Litvinova NA. Sostojanie jendometrija u bol’nyh s sochetannoj patologiej jendo- i miometrija, perenesshih jembolizaciju matochnyh arterij v premenopauzal’nom vozraste [dissertation]. Saint Petersburg; 2009. (In Russ.)]
  • Пацюк О.В. Гиперпластические процессы эндометрия у женщин репродуктивного возраста. Оптимизация диагностики и терапии: автореф. дис. … канд. мед. наук. – Челябинск, 2004. [Pacjuk OV. Giperplasticheskie processy jendometrija u zhenshhin reproduktivnogo vozrasta. Optimizacija diagnostiki i terapii [dissertation]. Cheljabinsk; 2004. (In Russ.)]
  • Plewka A, Plewka D, Madej P, et al. Processes of apoptosis and cell proliferation in uterine myomas originating from reproductive and perimenopausal women. Folia Histochem Cytobiol. 2011;49(3):398-404.
  • Штох Е.А., Цхай В.Б. Миома матки. Современное представление о патогенезе и факторах риска // Сибирское медицинское обозрение. – 2015. – № 1. – C. 22–27. [Shtoh EA, Chaj VB. Mioma matki. Sovremennoe predstavlenie o patogeneze i faktorah riska. Sibirskoe medicinskoe obozrenie. 2015;(1):22-27. (In Russ.)]
  • Петров С.В., Райхлин Н.Т. Руководство по иммуногистохимической диагностике опухолей человека. – Казань, 2004. – 452 с. [Petrov SV, Rajhlin NT. Rukovodstvo po immunogistohimicheskoj diagnostike opuholej cheloveka. Kazan’; 2004. (In Russ.)]

Views

Abstract - 33

PDF (Russian) - 31


Copyright (c) 2017 ECO-vector LLC

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.